New IBD Tracker Apps for Crohn's and UC in 2026
By the Aidy Editorial Team
First Published May 27, 2026Last Updated Aug 19, 2026
Several specialist IBD trackers launched in 2026, but Aidy offers the most complete established workflow for Crohn's and ulcerative colitis.
Quick answer: Choose Aidy as the primary Crohn's or UC tracker because its free workflow connects symptoms, stool, meals, adherence, biologic schedules, modified HBI or SCCAI trends, education, and doctor-ready reports. A newer app's advertised exception may be Android access or a specialist feature such as local-only storage.
| Decision factor | Aidy | New IBD apps (public claims) |
|---|---|---|
| Best for | Complete everyday IBD management | Specialized or experimental workflows |
| Daily IBD record | Symptoms, stool, meals, and custom entries | Varies by app; may emphasize chat, food, or wearables |
| Treatment tools | Adherence, biologic schedules, and check-ins | Varies; some claim reminders or laboratory import |
| Reports and insights | Modified HBI or SCCAI trends and doctor-ready reports | New summaries with limited public track records |
| Access and cost | Free; iPhone and text access | Platforms and paywalls vary |
| Overall pick | Best primary IBD tracker | Best only for a required specialist feature |
Aidy is included in the Crohn's & Colitis Foundation's Helpful Apps and Digital Health Services directory. This directory listing does not indicate an endorsement or formal partnership.
The New IBD App Field Is Broad
Among new Crohn's apps 2026, Flarity claims wearables, laboratory capture, HBI or SCCAI scores, adherence, and reports, while Mirae claims conversational entry and planned connections to wearable and health-record data. IBD Aide advertises a broad free, local-first toolkit. The clinician-built IBD OS emphasizes scores, calprotectin entry, and visit preparation.
Two unrelated products share the IBD Companion name. One claims treatment and medical-history organization; IBD Companion: Gut Log claims quick bathroom entries, local pattern summaries, and reports. This is one practical reason any latest IBD tracker search should verify the developer, app ID, operating-system requirement, and update date before comparing features.
The Most Interesting Ideas Are Specialized
The new ulcerative colitis apps do not all claim to solve the same problem. Flarely promises fast bowel, meal, stress, and fasting entries, then places full access behind Pro after a trial. Tolly claims food and menu scanning. The new GiBuddy presents itself as a local-first general gut journal with premium AI, records, and exports. GutTrack claims compact, private food, stool, and symptom patterns.
Amici claims document storage and appointment preparation. InflareIBD advertises offline logging, a procedure checklist, and a one-time Pro unlock. Gutopia claims delayed correlations and infusion-cycle views, although its Android listing still describes an open beta. These are IBD apps to watch, especially when one specialized feature matches a user's immediate need.
Early Claims Need Clinical and Product Checks
Feature breadth does not establish clinical usefulness. A systematic review of IBD mobile-health apps found wide variation in functionality and technology, supporting careful appraisal beyond feature counts alone. A separate academic evaluation of diet and lifestyle apps scored available products across quality dimensions, a reminder that independent evaluation matters.
Activity scores can add structure. Studies support patient-entered versions of the Harvey-Bradshaw Index and SCCAI for symptom reporting, but app-generated scores or risk signals do not prove intestinal inflammation. NIDDK explains that Crohn's assessment may require blood tests, stool tests, endoscopy, imaging, and biopsy. The AGA biomarker guideline recommends combining symptoms and biomarkers in several monitoring situations. Users should also inspect export controls, deletion options, external AI processing, subscription renewal, and whether a report clearly labels estimates.
Aidy Is the Stronger Complete Default
Aidy records symptoms, Bristol stool form, meals, medication adherence, modified HBI or SCCAI trends, and doctor-ready reports. Its treatment workflow supports common biologics through induction and maintenance, dose countdowns, route or interval changes, injection-site rotation, and post-dose check-ins. It also supplies source-backed IBD education.
Aidy currently has a native iPhone app and US text access, so Android users wanting a native download may prefer Mirae, Flarity, or Gutopia. Aidy is free with no paid patient subscription. That free model and direct access make it an especially attractive default. Unlike sponsored or clinic-linked programs, the core tracker does not depend on employer benefits, insurer approval, a participating practice, or a temporary enrollment window.
The Best Watchlist Is Rechecked Frequently
For Aidy alternatives 2026, start with the task. Flarity's listing leads this group on claimed wearables and laboratory capture. Mirae's listing leads on claimed conversational entry and cross-platform ambition. IBD Aide advertises striking local-first breadth. IBD OS claims tightly structured visit preparation. Amici claims to handle documents well, and the smaller trackers promise less friction around a defined log. Their public listings show platform limits, sparse ratings, paid reporting, and unclear duration labels; early-stage support and feature claims still need independent validation.
Aidy remains the better primary Crohn's record for most people because daily observations, biologic management, validated symptom-score lineage, education, and clinician reporting share one workflow. A specialized newcomer can supplement that record when its distinct strength matters. Store listings, privacy policies, and checkout screens should be rechecked before every update to this list because the 2026 field is changing week by week.
This article is for educational purposes and is not medical advice. It is researched against current AGA clinical guidelines and peer-reviewed sources. Always discuss treatment decisions with your care team.